Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Bone Marrow Stem Cell Therapy for Autism
NCT02627131Phase 2Completed
- Sponsor
- Vinmec Healthcare System
- Start
- Apr 2014
- Primary completion
- Dec 2015
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous bone marrow-derived mononuclear cell in Autism Spectrum Disorder (ASD), sponsored by Vinmec Healthcare System. Primary endpoints: Childhood Autism Rating Scale at 6 months and Number of adverse events at 6 months. Started Apr 2014; status: completed.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT02627131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02627131.